

Amendments to the Claims:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Canceled)

37. (Canceled)

38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Canceled)

42. (Canceled)

43. (Canceled)

44. (New) A method for treating a symptom of a lower urinary tract disorder, comprising:
- (a) administering an $\alpha_2\delta$ subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin; and
 - (b) administering an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride;
- wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are in therapeutically effective amounts sufficient to treat a symptom of a lower urinary tract disorder.
45. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are contained within a single pharmaceutical formulation.
46. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are contained within separate pharmaceutical formulations.
47. (New) The method of claim 46, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are administered concurrently.
48. (New) The method of claim 46, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are administered sequentially.
49. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are administered on an as-needed basis.
50. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are administered prior to commencement of an activity wherein suppression of the symptoms of a lower urinary tract disorder would be desirable.

51. (New) The method of claim 50, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are administered from about 0 to about 3 hours prior to commencement of an activity wherein suppression of said symptoms would be desirable.

52. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are administered orally, transmucosally, sublingually, buccally, intranasally, transurethrally, rectally, by inhalation, topically, transdermally, parenterally, intrathecally, vaginally, or perivaginally.

53. (New) The method of claim 44, wherein the symptom of a lower urinary tract disorder is associated with benign prostatic hyperplasia or overactive bladder.

54. (New) The method of claim 44, wherein the symptom of a lower urinary tract disorder is urinary frequency.

55. (New) The method of claim 44, wherein the symptom of a lower urinary tract disorder is urinary urgency.

56. (New) The method of claim 44, wherein the symptom of a lower urinary tract disorder is nocturia.

57. (New) The method of claim 44, wherein the symptom of a lower urinary tract disorder is incontinence.

58. (New) The method of claim 44 wherein at least one detrimental side effect associated with single administration of said $\alpha_2\delta$ subunit calcium channel modulator or single administration of said antimuscarinic is lessened by concurrent administration of said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic.

59. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Oxybutynin.

60. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Tolterodine.

61. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Propiverine.

62. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Solifenacin monohydrochloride.

63. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Oxybutynin.

64. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Tolterodine.

65. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Propiverine.

66. (New) The method of claim 44, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Solifenacin monohydrochloride.

67. (New) A pharmaceutical composition comprising:

- (a) an $\alpha_2\delta$ subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin; and
- (b) an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride;

and wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are in therapeutically effective amounts sufficient to treat a symptom of a lower urinary tract disorder.

68. (New) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator is present in an amount from about 50 mg to about 2400 mg, and wherein said antimuscarinic is present in an amount equal to or less than about 5 mg.

69. (New) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator is in an amount of about 200 mg.

70. (New) The pharmaceutical composition of claim 67 wherein said antimuscarinic is in an amount of about 2.5 mg.

71. (New) The pharmaceutical composition of claim 67 wherein said antimuscarinic is in an amount of about 1.25 mg.

72. (New) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are present in a ratio from about 1:1 to about 800:1 or from about 1:1 to about 1:800, respectively, based on a fraction of their respective ED₅₀ values.

73. (New) The pharmaceutical composition of claim 67 wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are in a weight/weight ratio of from 1:1 to about 800:1 or from about 1:1 to about 1:800, respectively.

74. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are formulated for oral, transmucosal, sublingual, buccal, intranasal, transurethral, rectal, inhalation, topical, transdermal, parenteral, intrathecal, vaginal, or perivaginal administration.

75. (New) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is associated with benign prostatic hyperplasia or overactive bladder.

76. (New) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is urinary frequency.

78. (New) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is urinary urgency.

79. (New) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is nocturia.

80. (New) The pharmaceutical composition of claim 67, wherein the symptom of a lower urinary tract disorder is incontinence.

81. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Oxybutynin.

82. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Tolterodine.

83. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Propiverine.

84. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Solifenacin monohydrochloride.

85. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Oxybutynin.

86. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Tolterodine.

87. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Propiverine.

88. (New) The pharmaceutical composition of claim 67, wherein said $\alpha_2\delta$ subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Solifenacin monohydrochloride.

89. (New) A pharmaceutical composition comprising Oxybutynin, wherein said Oxybutynin is in an amount less than about 2.5 mg.

90. (New) A packaged kit for use in the treatment of a symptom of a lower urinary tract disorder, comprising:

- (a) an $\alpha_2\delta$ subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin;
- (b) an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride;
- (c) a container housing said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic during storage and prior to administration; and
- (d) instructions for carrying out drug administration of said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic in a manner effective to treat said symptom of a lower urinary tract disorder.

91. (New) The packaged kit of claim 90 wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are contained in the same pharmaceutical formulation.

92. (New) The packaged kit of claim 90 wherein said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic are contained in separate pharmaceutical formulations.

93. (New) The packaged kit of claim 92 wherein said instructions include directions for carrying out drug administration of said $\alpha_2\delta$ subunit calcium channel modulator and said antimuscarinic sequentially or concurrently.

94. (New) A packaged kit for use in the treatment of a symptom of a lower urinary tract disorder, comprising:

- (a) an $\alpha_2\delta$ subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin;
- (b) a container housing said $\alpha_2\delta$ subunit calcium channel modulator during storage and prior to administration; and

instructions for carrying out drug administration of said $\alpha_2\delta$ subunit calcium channel modulator sequentially or concurrently with an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride, in a manner effective to treat said symptom of a lower urinary tract disorder.

95. (New) A packaged kit for use in the treatment of a symptom of a lower urinary tract disorder, comprising:

- (c) an antimuscarinic selected from the group consisting of Oxybutynin, Tolterodine, Propiverine, and Solifenacin monohydrochloride;
 - (d) a container housing said antimuscarinic during storage and prior to administration; and
- instructions for carrying out drug administration of said antimuscarinic sequentially or concurrently with an $\alpha_2\delta$ subunit calcium channel modulator selected from the group consisting of Gabapentin and Pregabalin, in a manner effective to treat said symptom of a lower urinary tract disorder.